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Introduction and background
===========================

The differential diagnosis (DD) of intracranial tumors (ICTs) is a dubious task, requiring a highly trained neuropathologist and a set of both classical and immunohistochemical (IHC) markers for pinpointing the correct diagnosis \[[@REF1]\]. The histological verification of the tumor entries is key in determining the optimal genetic tests needed for subtyping as per the revised 2016 World Health Organization criteria (WHO) and providing the patients with the optimal treatment \[[@REF1]\].

Review
======

Before the morphological evaluation, the surgical report of gross tumor characteristics, place of origin of the tumor, together with the aid of any radiological report available, can be very suggestive of different tumor entries (Figure [1](#FIG1){ref-type="fig"}) \[[@REF2]\].

Despite morphology on hematoxylin and eosin (H&E) being highly suggestive in some cases, often IHC is also needed to distinguish between different entries, especially in cases of only small tumor fragments being sent for pathological investigation. Although IHC is a useful tool in the DD of any lesion, when regarding ICTs, it is especially important to avoid some common pitfalls due to antigen mimicry such as the glial fibrillary acidic protein (GFAP) mimicry with epithelial membrane antigen (EMA) and the pan-cytokeratin (CK AE1/AE3), where if all three reactions are positive, only the GFAP one should be considered valid \[[@REF3]-[@REF6]\].

![Diagnostic algorithm based on gross and histological features, with key IHC markers\
IHC: immunohistochemistry; WHO: World Health Organization; GFAP: glial fibrillary acidic protein; CK AE1/AE3: pan-cytokeratin; EMA: epithelial membrane antigen; HPF: high-power field; OLIG2: oligodendrocyte transcription factor; ETMR: embryonal tumor with multilayered rosettes; PNET: primitive neuroectodermal tumor; GIT: gastrointestinal tract; GUT: genitourinary tract; CNS: central nervous system](cureus-0011-00000006384-i01){#FIG1}

Tumors of the cranial nerves

Cranial nerve tumors are relatively rare, among other ICTs. The two main entries in this category are Schwannoma - a benign tumor and malignant peripheral nerve sheath tumor (MPNST) - its malignant counterpart \[[@REF7]\]. Schwannomas classically present with Antony A and B zones, with pathognomonic Verocay bodies (Figure [2](#FIG2){ref-type="fig"}). However, when histologically verifying on small tissue fragment, sometimes the DD between the two entries is difficult. In this case, an IHC stain with Ki-67 is useful - Schwannomas do not give a positive reaction, whilst MPNSTs have a high percentage of positive nuclei. MPNSTs are also p53 positive on IHC.

![Typical appearance of Verocay bodies in Schwannoma. H&E stain, original magnification 100x\
H&E: hematoxilyn and eosin](cureus-0011-00000006384-i02){#FIG2}

Tumors of the sellar region

Often an underlooked region, when considering ICTs as again surgical and radiological reports may prove highly informative, especially in cases where the patient has abnormal hormone levels, further pointing to the type of adenoma of the pituitary \[[@REF8]\]. Even in such cases, it is useful to also consider pituitary carcinomas, which have a high Ki-67 percentage of positive nuclei, unlike adenomas and also craniopharyngiomas - a disgerminative squamous cell tumor positive for EMA, CK AE1/AE3 and p53 (Figure [3](#FIG3){ref-type="fig"}) \[[@REF9]\].

![Typical appearance of craniopharyngioma. H&E stain, 100x\
H&E: hematoxylin and eosin](cureus-0011-00000006384-i03){#FIG3}

Tumors of the meninges

Meningeal tumors can pose a difficulty in the DD, especially the more anaplastic types which may also have deep invasion into the brain. Also important to consider here is the surgical and radiological report. If the tumor is diffuse then it is much more likely to be a distant metastasis. Such tumor involvement from the meninges have the IHC profile of the primary lesion and generally EMA and CK AE1/AE3 positive with a high Ki-67 index.

Classical tumors of the meninges are the meningioma group, graded WHO, based on their histological profile. WHO grade I tumor (Figure [4](#FIG4){ref-type="fig"}) present with minimal to no cellular atypia, no mitotic figures and do not invade the brain parenchyma, while WHO grade II (Figure [5](#FIG5){ref-type="fig"}) meningiomas show brain parenchyma invasion and may present with up to 20 mitotic figure per 10 high-power fields (HPF) \[[@REF10]-[@REF12]\]. WHO grade III meningiomas (Figure [6](#FIG6){ref-type="fig"}) also have brain parenchyma invasion, cellular atypia, more than 20 mitotic figures per 10 HPF or may even have a sarcomatoid differentiation \[[@REF2]\].

![WHO grade I meningioma - no mitotic figures or brain parenchyma invasion. H&E stain original magnification 100x\
WHO: World Health Organization; H&E: hematoxylin and eosin](cureus-0011-00000006384-i04){#FIG4}

![WHO grade II meningioma. H&E stain original magnification 400x\
WHO: World Health Organization; H&E: hematoxylin and eosin](cureus-0011-00000006384-i05){#FIG5}

![WHO grade III meningioma with brain parenchyma invasion. H&E stain original magnification 100x\
WHO: World Health Organization; H&E: hematoxylin and eosin](cureus-0011-00000006384-i06){#FIG6}

Useful marker in the differentiation between metastasis and meningiomas, regardless of WHO grade are IHC marking with vimentin and S100, with up to 70% showing positive reaction with EMA, without a reaction for CK AE1/AE3 \[[@REF11]\].

Tumors originating from the choroid plexus

Normally these tumors present in the pediatric population, with some of them being congenital. The two main entries here are the choroid plexus papilloma (CPP) - a benign entry and its malignant counterpart - choroid plexus carcinoma (CPC) \[[@REF13]\]. DD between the two should be considered on histological criteria alone with CPP having no cellular atypia and mitotic figures, highly similar to a normal choroid plexus, with more hyperchromic cytoplasm due to glycogen accumulation, whilst CPC has cellular atypia to some extent and presence of mitotic figures (Figure [7](#FIG7){ref-type="fig"}) \[[@REF14]\].

![Choroid plexus carcinoma. H&E stain, original magnification 100x\
H&E: hematoxylin and eosin](cureus-0011-00000006384-i07){#FIG7}

Tumors of the brain parenchyma

The biggest group, both based on incidence and individual entries. The DD here can be especially difficult, with the lack of medical information regarding the condition of the patient and in some cases the inability of the patient to share information regarding his past condition. Even in cases with a patient with a well known distant malignancy, the possibility of synchronous central nervous system (CNS) tumor should always be considered.

Whilst metastatic conditions often present as well-circumscribed masses, often multiple, they may present as solitary lesions mimicking the gross and radiological appearance of a primary tumor.

When considering the DD of such lesion it is best to start the diagnostic process with their gross appearance.

Cystic lesions

A relatively small percentage of brain tumors. The highest rate of cystic tumors is attributed to CNS metastasis, which presents with the IHC profile of the primary lesion and is generally EMA and CK AE1/AE3 positive, with a high Ki-67 index. Another entry in this group is the WHO grade pilocytic astrocytoma (Figure [8](#FIG8){ref-type="fig"}) - a tumor with astrocytic glial differentiation, presenting as a pilocytic rich, GFAP positive lesion, predominantly in the pediatric population. WHO grade I astrocytomas are an important factor for the further development of higher WHO grade glial tumors \[[@REF2]\]. Furthermore, it is important to also note the rich amount of pathological processes in the CNS that can present as cystic lesions, both primary and secondary, such as pseudocysts, echinococcosis, abscesses or epidermoid cysts.

![Pilocytic (WHO grade I) astrocytoma, H&E stain, original magnification 100x\
WHO: World Health Organization; H&E: hematoxylin and eosin](cureus-0011-00000006384-i08){#FIG8}

Solid lesions

DD of solid brain parenchyma lesions should always start with the depiction or lack thereof of Scherer structures. Hans Joachim Scherer was a German pathologist, devout to the pathology of CNS tumors and established a wide set of histological criteria, based on a hematoxylin and eosin (H&E) stain, which are the basis of the WHO grading of glial tumors (Figures [9](#FIG9){ref-type="fig"}-[10](#FIG10){ref-type="fig"}) \[[@REF15]-[@REF18]\].

![Diffuse (WHO grade II) astrocytoma, H&E stain, original magnification 100x\
WHO: World Health Organization; H&E: hematoxylin and eosin](cureus-0011-00000006384-i09){#FIG9}

![Anaplastic (WHO grade III) astrocytoma, H&E stain, original magnification 100x\
WHO: World Health Organization; H&E: hematoxylin and eosin](cureus-0011-00000006384-i10){#FIG10}

Important to consider here are the so-called primary Scherer structures - foci of pseudopalisading necrosis, pathognomonic for glioblastoma multiforme (GBM), a WHO grade IV astrocytic glial neoplasm (Figure [11](#FIG11){ref-type="fig"}). Secondary Scherer structures, as described by Scherer, are histological patterns based on the spread, growth and biological potential of glial tumors. These include subpial palisading of tumor cells, satellitosis of tumors cell around preserved neurons and blood vessels, tractal aggregation of tumors cells and the nearly pathognomonic glomeruloid vascular proliferation (Figures [12](#FIG12){ref-type="fig"}-[16](#FIG16){ref-type="fig"}). Key here are the patterns of growth of glial neoplasm, although aggressive in their growth and clinical course, these tumors take a long time to destroy the normal brain structures, unlike lower WHO grade meningiomas for example, and therefore as a definition present late clinically with an excessive in size tumor mass. The glomeruloid vascular proliferation, although being a factor of tumor growth and a distinct phenomenon from the other, should also be considered together with them as a key feature pointing towards a glial tumor, regardless of the WHO grade.

![Primary Scherer figure (pseudopalisadic necrosis), H&E stain, original magnification 100x\
H&E: hematoxylin and eosin](cureus-0011-00000006384-i11){#FIG11}

![Glomeruloid vascular proliferation, H&E stain, original magnification 100x\
H&E: hematoxylin and eosin](cureus-0011-00000006384-i12){#FIG12}

![Perineural satelitosis, H&E stain, original magnification 400x\
H&E: hematoxylin and eosin](cureus-0011-00000006384-i13){#FIG13}

![Vascular satelitosis, H&E stain, original magnification 400x\
H&E: hematoxylin and eosin](cureus-0011-00000006384-i14){#FIG14}

![Tractal aggregation, H&E stain, original magnification 200x\
H&E: hematoxylin and eosin](cureus-0011-00000006384-i15){#FIG15}

![Subpial aggregation (palisading), H&E stain, original magnification 100x\
H&E: hematoxylin and eosin](cureus-0011-00000006384-i16){#FIG16}

As already mentioned primary Scherer figures are pathognomonic for GBM, with secondary Scherer figures also being present, although rarely being reported on histology. GBMs show a distinct IHC profile with GFAP, Vimentin and S100 positivity. It is important to consider that around 2% of GBM lose their IHC reaction with GFAP, whilst preserving their vimentin reaction. Also key to note here is the already mentioned antigen mimicry reactions with EMA and CK AE1/AE3 \[[@REF5]\]. Like all other glial tumors with astrocytic differentiation, GBM has a varying Ki-67 index, which cannot be used to determine the WHO grade alone.

An often underdiagnosed tumor also presenting with primary and secondary Scherer structures is gliosarcoma, a WHO grade IV tumor. Gliosarcoma (Figures [17](#FIG17){ref-type="fig"}) although a distinct entry, shares most of its features with GBM. However, the presence of a mesenchymal component with sarcomatoid features is key. Also important here is the IHC profile diffusely positive for vimentin, with a patchy expression for GFAP, only in the glial component of the tumor.

![Gliosarcoma, (A) H&E stain, original magnification 40x and (B) GFAP IHC stain, original magnification 40x\
H&E: hematoxylin and eosin; GFAP: glial fibrilary acidic protein; IHC: immunohistochemistry](cureus-0011-00000006384-i17){#FIG17}

If there are no primary Scherer structures on H&E, this does not exclude the diagnosis of GBM. Tumors rich in secondary Scherer structures should be subjected to IHC evaluation, as IHC with GFAP especially may outline the poorly defined pseudopalisading necrotic foci. If such is not outlined by IHC, then a diagnosis of a glial tumor WHO grade II or III should be considered. If located on the midline or the basal ganglia, the diagnosis of diffuse midline glioma should be considered, regardless of WHO criteria adherence to an individual grade.

Astrocytomas WHO grade II (Figure [9](#FIG9){ref-type="fig"}) are GFAP positive, show limited cellular atypia, a fibrillary background, and no mitotic figures, whist astrocytomas WHO grade III (Figure [10](#FIG10){ref-type="fig"}) have cellular atypia, although limited, are densely hypercellular and may present with abundant mitotic figures \[[@REF2]\].

The absence of Scherer figures on H&E and IHC should sway the pathologist in the direction of more rare primary entries or metastasis if GFAP negative. The presence of a distinct oligodendrocyte-like component of the tumor should point to either oligodendroglioma (Figure [18](#FIG18){ref-type="fig"}) - GFAP and (oligodendrocyte transcription factor) OLIG2 positive or oligoastrocytoma - OLIG2 expression in the oligodendrocytic component and diffuse GFAP expression, stronger in the astrocytic component.

![Oligodendroglioma, H&E stain, original magnification 100x\
H&E: hematoxylin and eosin](cureus-0011-00000006384-i18){#FIG18}

The absence or limited amount of Scherer structures, with the absence of an oligodendrocytic component, should sway the pathologist to search for rosettes or pseudorosettes and again consult the surgical and radiological report \[[@REF2],[@REF19],[@REF20]\].

Subtentorial tumors with rosettes are predominantly medulloblastomas (Figure [19](#FIG19){ref-type="fig"}), which are synaptophysin and NeuN positive, with a minority of such subtentorial tumors being the embryonal tumors with multilayered rosettes (ETMR), previously referred to as primitive neuroectodermal tumors (PNET) (Figure [19](#FIG19){ref-type="fig"}) which are synaptophysin negative and have a patchy vimentin expression. ETMRs are much more common with a supratentorial location.

![(A) Medulloblastoma, H&E stain, original magnification 100x; (B) ETMR, H&E stain, original magnification 400x; ependymoma, H&E stain, original magnification 200x; (C) Ependimoma, H&E stain, original magnification 200x\
H&E: hematoxylin and eosin; ETMR: embryonal tumor with multilayered rosettes](cureus-0011-00000006384-i19){#FIG19}

Other tumors with rosettes or pseudorosettes are the ependymoma (Figure [19](#FIG19){ref-type="fig"}) and subependymoma tumors, both of which have at least in some capacity a connection to the ventricular system. Generally on IHC ependymomas are vimentin, GFAP and EMA positive, while subependymomas despite their varying and non-specific IHC profile have Ki-67 index of \<1%.

Metastasis

The most common metastatic entries to the CNS are from the lungs, breast, gastrointestinal tract, genitourinary tract and melanomas \[[@REF21],[@REF22]\]. Despite sometimes phenotypically different and hard to identify these lesions always preserve the IHC profile of the primary lesion, contrasting from the IHC profile of primary CNS tumors (Table [1](#TAB1){ref-type="table"}).

###### IHC profile of the most common ICT by differentiation

\* dependant on the type of metastasis; GFAP: glial fibrillary acidic protein; OLIG2: oligodendrocyte transcription factor; CK AE1/AE3: pan-cytokeratin; EMA: epithelial membrane antigene; SMA: smooth muscle actin

  --------------- --------------------------- ------------------ ----------- ----------- --------------
  antibody        astrocytic                  oligodendrocytic   meningeal   embryonal   metastasis\*
  GFAP            \+                          \+                 \-          +/-         \-
  OLIG2           \-                          \+                 \-          \-          \-
  NeuN            in preserved neurons only   \-                 \-          +/-         \-
  Synaptophysin   \+                          \-                 \-          \+          +/-
  CK AE1/AE3      +/-                         \-                 \-          +/-         +/-
  EMA             +/-                         \-                 \+          \-          +/-
  Vimentin        \+                          \-                 \+          +/-         +/-
  SMA             \-                          \-                 \+          \-          +/-
  S100            \+                          \+                 \+          +/-         +/-
  Ki-67           variable                    low                variable    high        high
  --------------- --------------------------- ------------------ ----------- ----------- --------------

Other tumors

Some rare tumors, which do not fit the above-mentioned criteria include infiltration or primary lymphoproliferative disorders, infiltration from hematological malignancies, mesenchymal tumors, pineocytoma and even easily diagnosable, although rare tumors such primary CNS lipoma (Figures [20](#FIG20){ref-type="fig"}-[23](#FIG23){ref-type="fig"}) \[[@REF23]\].

![Hemangioblastoma, H&E stain, original magnification 100x\
H&E: hematoxylin and eosin](cureus-0011-00000006384-i20){#FIG20}

![Cranial chordoma, H&E stain, original magnification 40x\
H&E: hematoxylin and eosin](cureus-0011-00000006384-i21){#FIG21}

![Ganglioglioma, H&E stain, original magnification 100x\
H&E: hematoxylin and eosin](cureus-0011-00000006384-i22){#FIG22}

![Diagnostic algorithm based on histogenesis of tumors\
OLIG2: oligodendrocyte transcription factor; GFAP: glial fibrillary acidic protein; EMA: epithelial membrane antigene; IHC: immunohistochemistry](cureus-0011-00000006384-i23){#FIG23}

Primary tumor classification, according to WHO

As per the 2016 revision of the WHO classification of tumors of the CNS, even if histologically defined, the tumors should always be identified as not otherwise specified (NOS), unless IHC or genetic analysis is performed to identify the subgroup of mutations relevant to the specific tumor entry, such as isocitrate dehydrogenase (IHD), 1p/19q, and ATRX \[[@REF2],[@REF20]\]. In rare instances, primary tumors may also be identified as not elsewhere classified (NEC) \[[@REF24]-[@REF28]\]. NEC should be used in cases when extensive genetic testing was performed on a specific histological entry, however, the result from the test does not allow for inclusion into any of the specified WHO diagnoses.

Conclusions
===========

The diagnosis and DD of intracranial tumors require a systematic approach, acquaintance with the clinical, surgical and radiological documentation of the patient and in-depth knowledge of the diagnostic criteria of the different groups of tumors. The diversity of the tumors, based both on their primary and metastatic origin, together with the diversity of the primary lesions, their criteria of WHO grading and varying IHC profile, together with the genetic alterations defined in the 2016 revision of the WHO classification makes the morphological diagnosis of CNS tumors a challenging task, requiring multiple modalities for defining the tumor type.
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